TY - JOUR
T1 - Bupropion in the treatment of outpatients with asthma and major depressive disorder
AU - Brown, E. Sherwood
AU - Vornik, Lana A.
AU - Khan, David A.
AU - Rush, A. John
PY - 2007
Y1 - 2007
N2 - Objective: Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients. Method: We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology - Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12. Results: Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8% of the patients were responders and 16.7% were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1% Predicted and HAM-D-17 r = -0.66, p = 0.006). Conclusions: Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.
AB - Objective: Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients. Method: We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology - Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12. Results: Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8% of the patients were responders and 16.7% were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1% Predicted and HAM-D-17 r = -0.66, p = 0.006). Conclusions: Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.
KW - Asthma
KW - Bupropion
KW - Major depressive disorder
UR - http://www.scopus.com/inward/record.url?scp=34547611313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547611313&partnerID=8YFLogxK
U2 - 10.2190/D235-2285-2121-6724
DO - 10.2190/D235-2285-2121-6724
M3 - Article
C2 - 17645195
AN - SCOPUS:34547611313
SN - 0091-2174
VL - 37
SP - 23
EP - 28
JO - International Journal of Psychiatry in Medicine
JF - International Journal of Psychiatry in Medicine
IS - 1
ER -